IL-17 receptor antagonist (Protagonist Therapeutics)

N/A

Report date: 2025/06/11 11:18:42
NME

Base Information

Drug NameIL-17 receptor antagonist (Protagonist Therapeutics)
Drug Alias NameOral IL-17 receptor antagonist
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionInterleukin-17 inhibitors
TargetsInterleukin-17
Therapy Area/IndicationsPlaque psoriasisPsoriasisSkin Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProtagonist Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtagonist Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisSkin Diseases +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A